The promise of precision oncology just hit a significant roadblock in colorectal cancer treatment, challenging assumptions about how liquid biopsies should guide therapeutic decisions. This setback could reshape clinical protocols for monitoring cancer survivors and raises questions about when intervention should begin after surgery. The ALTAIR phase 3 trial tested whether trifluridine/tipiracil hydrochloride could prevent disease recurrence in colorectal cancer patients whose circulating tumor DNA (ctDNA) turned positive during post-surgical monitoring. Despite 742 participants in this randomized, double-blind study, the oral chemotherapy combination showed no significant improvement in disease-free survival compared to placebo. The trial specifically targeted patients whose blood tests detected cancer DNA fragments months after their tumors were surgically removed, representing an early signal of potential recurrence. This negative result carries substantial implications for the emerging field of minimal residual disease monitoring. While ctDNA testing has shown remarkable sensitivity in detecting microscopic cancer persistence, this study suggests that identifying the problem and solving it are entirely different challenges. The failure may indicate that by the time ctDNA becomes detectable, micrometastases have already established themselves beyond the reach of current chemotherapy regimens. Alternatively, the specific drug combination may simply lack sufficient potency for this clinical scenario. This represents more than an incremental setback—it potentially undermines a core assumption driving billions in liquid biopsy investment. The oncology field had increasingly embraced the concept that early molecular detection would enable preemptive treatment, but ALTAIR suggests the therapeutic window may be narrower than anticipated. Future trials will likely need to explore more aggressive combinations, earlier intervention timepoints, or entirely different therapeutic approaches to capitalize on ctDNA's diagnostic capabilities.